Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 530125 | NSE Symbol : | ISIN : INE103E01016 | Industry : Pharmaceuticals - Indian - Bulk Drugs |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
23-Jun-2025	13-Aug-2025	Quarterly Results	Samrat Pharmachem Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2025 inter alia to consider and approve the un-audited financial results for the quarter ended 30-06-2025
16-Jul-2025	16-Jul-2025	Change in Directors	Appointment of Mr. Piyush Gangji Dharod as Non-Executive Independent Director of the Company w.e.f. July 16, 2025
26-Mar-2025	30-May-2025	Final Dividend	Samrat Pharmachem Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2025 inter alia to consider and approve the Audited Standalone Financial Results of the Company for the financial year ended March 31 2025 Outcome of Board Meeting held today (As per BSE Announcement Dated on 30/05/2025)
31-Dec-2024	14-Feb-2025	Quarterly Results	SAMRAT PHARMACHEM LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2025 inter alia to consider and approve the Un-audited financial results of the company for the quarter ended December 31 2024 The Board has considered and took on record the Un-audited Financial Results for the quarter ended December 31, 2024 Due to inadvertence, the start & end time of Board meeting was input in Indian time (02:00 To 03:30) instead of international time zone (14:00 To 15:30). The correct date & time of board meeting is as under: Date of board meeting: 14-02-2025 Commencement time: 14:00 hrs End time: 15:30 hrs Due to inadvertence, the start and end time of the Board Meeting held today was input in Indian time (02:00 to 03:30) instead of international time zone (14:00 to 15:30) during the filing of outcome of board meeting under corporate announcements. Correct Start & End time is: Start: 14:00 hrs End: 15:30 hrs (As Per BSE Announcement Dated on 14.02.2025)
27-Sep-2024	14-Nov-2024	Quarterly Results	SAMRAT PHARMACHEM LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2024 inter alia to consider and approve the Un-Audited Financial results of the company for the quarter and half year ended September 30 2024 Un-audited financial results for the quarter and half year ended September 30, 2024 (As per BSE Announcement dated on 14/11/2024)
29-Jun-2024	13-Aug-2024	Quarterly Results	SAMRAT PHARMACHEM LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2024 inter alia to consider and approve the Un-Audited Financial Results of the Company under Indian Accounting Standards (Ind-As) for the quarter ended June 30 2024. The Board has considered and took on record the Un-audited Financial Results for the quarter ended June 30, 2024. (As Per BSE Announcement Dated on: 13/08/2024)
25-Jul-2024	23-Jul-2024	Change in Directors	Appointment of Mr. Manishkumar Indukumar Pipalia and Mr. Sachin Samir Kothary as Non-Executive Independent Directors of the Company for a term of 5 consecutive years each with effect from July 23, 2024, subject to approval of the shareholders at the forthcoming 32nd AGM
28-Mar-2024	30-May-2024	Accounts	SAMRAT PHARMACHEM LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2024 inter alia to consider and approve the Audited Standalone Financial Results of the company for the quarter and year ended March 31 2024. The Board of Directors may consider a proposal to recommend dividend on the equity shares of the company for the financial year ended March 31 2024. Final Dividend & Audited Results (As per BSE Bulletin dated on 28/03/2024) The Board of Directors approved and adopted Audited Financial Results for the quarter and year ended March 31, 2024. Recommendation of Dividend @ 10% on paid up capital of the company (As Per BSE Announcement dated on 30.05.2024)
29-Dec-2023	14-Feb-2024	Quarterly Results	SAMRAT PHARMACHEM LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2024 inter alia to consider and approve Pursuant to Regulation 29(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 notice is hereby given that a meeting of the Board of Directors of the Company will be held at 03:00 P.M. on Wednesday the 14th day of February 2024 at the Corporate Office of the Company at 701/702 Business Square M. A. Road Andheri (West) Mumbai - 400 058 inter alia to consider and take on record the Un-Audited Financial Results of the Company under Indian Accounting Standards (Ind-As) for the quarter ended December 31 2023. The Company shall intimate to the exchanges the Un-Audited financial results upon the conclusion of the aforesaid Board Meeting and will arrange for the announcement of the same in the Press and on the companys website as required under the Listing Agreement. We wish to inform you that the Board has considered and took on record the Un-Audited Financial Results of the company for the quarter ended December 31, 2023. (As Per BSE Announcement Dated on: 14/02/2024)
26-Sep-2023	08-Nov-2023	Quarterly Results	SAMRAT PHARMACHEM LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/11/2023 inter alia to consider and approve the un-audited standalone financial results for the quarter and half year ended September 30 2023 The Board at its meeting held today has considered and took on record the Un-audited financial results for the quarter and half year ended September 30, 2023 Approval of Results for the quarter and half year ended September 30, 2023 (As per BSE Announcement Dated on 08/11/2023) Newspaper Publication - Extract of UFR 30/09/2023 (As Per BSE Announcement Dated on 23/11/2023)
30-Jun-2023	14-Aug-2023	Quarterly Results	SAMRAT PHARMACHEM LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2023 inter alia to consider and approve the Un-Audited Financial Results of the Company under Indian Accounting Standards (Ind-As) for the quarter ended June 30 2023. SAMRAT PHARMACHEM LIMITED has informed BSE about Board Meeting to be held on 14 Aug 2023 to consider financial statements for the period ended June 2023. Financial results. We wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Monday, August 14, 2023, the Board has considered and took on record the attached Un-Audited Standalone Financial Results of the Company for the quarter ended June 30, 2023. The meeting of the Board of Directors of the Company commenced at 02:30 P.M. and concluded at 03:45 P.M. The Board of Directors at its meeting held today has considered and took on record the attached Un-audited Standalone Financial Results for the quarter ended June 30, 2023. (As Per BSE Announcement Dated on 14.08.2023)
28-Mar-2023	30-May-2023	Accounts	SAMRAT PHARMACHEM LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2023 inter alia to consider and approve the Audited Standalone Financial Results of the Company under Indian Accounting Standards (Ind-As) for the quarter and year ended March 31 2023 along with the Audit Reports of the Statutory Auditor thereon. In the aforementioned meeting the Board of Directors may also consider a proposal to recommend dividend on the equity shares of the Company for the financial year ended March 31 2023. Equity Rs.1.0000 per share(10%)Dividend (As Per BSE Bulletin Dated on 30.05.2023) Outcome of the Board Meeting of the Company held today (As Per BSE Announcement Dated on 30.05.2023)
01-Mar-2023	16-Mar-2023	Change in Directors	SAMRAT PHARMACHEM LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/03/2023 inter alia to consider and approve re-appointment of 3 Executive Directors of the company namely Mr. Lalit Mehta Chairman & Managing Director (DIN: 00216681) Mr. Rajesh Mehta Executive Director (DIN: 00216731) & Mr. Megh Mehta Executive Director (DIN: 07287394) for a further period of 3 years effective from April 1 2023 to March 31 2026 based on the recommendations of the Nomination & Remuneration Committee and to approve the re-appointment through the postal ballot. We wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Thursday, March 16, 2023, has appointed the following Directors on the recommendation of the Nomination and Remuneration Committee, details of which are as under: 1. Mr. Lalit Mehta (DIN: 00216681) re-appointed as the Chairman & Managing Director of the Company for a period of 3 years commencing from 1st April, 2023 2. Mr. Rajesh Mehta (DIN: 00216731) re-appointed as the Executive Director of the Company for a period of 3 years commencing from 1st April, 2023 3. Mr. Megh Mehta (DIN: 07287394) re-appointed as the Executive Director of the Company for a period of 3 years commencing from 1st April, 2023 The Board has adopted Succession Planning Policy under Regulation 17(4) of the Securities and Exchange Board of India (LODR) Regulations, 2015 effective from 16th March, 2023. The meeting of the Board of Directors of the Company commenced at 14:00 hrs and concluded at 15:30 hrs. (As Per BSE Announcement dated on 16.03.2023)
29-Dec-2022	14-Feb-2023	Quarterly Results	SAMRAT PHARMACHEM LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2023 inter alia to consider and approve Pursuant to Regulation 29(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 notice is hereby given that a meeting of the Board of Directors of the Company will be held at 02:30 P.M. on Tuesday the 14th day of February 2023 at the Corporate Office of the Company at 701/702 Business Square M. A. Road Andheri (West) Mumbai - 400 058 inter alia to consider and take on record the Un-Audited Financial Results of the Company under Indian Accounting Standards (Ind-As) for the quarter ended December 31 2022. We wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Tuesday, February 14, 2023, the Board has considered and took on record the attached Un-Audited Standalone Financial Results of the Company for the quarter ended December 31, 2022, which is enclosed herewith along with the Limited Review Report of the Statutory Auditor of the Company. The meeting of the Board of Directors of the Company commenced at 14:30 hrs and concluded at 16:00 hrs. (As per BSE Announcement Dated on 14/02/2023)
30-Sep-2022	14-Nov-2022	Quarterly Results	SAMRAT PHARMACHEM LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2022 inter alia to consider and approve Pursuant to Regulation 29(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 notice is hereby given that a meeting of the Board of Directors of the Company will be held at 02:00 P.M. on Monday the 14th day of November 2022 at the Corporate Office of the Company at 701/702 Business Square M. A. Road Andheri (West) Mumbai - 400 058 inter alia to consider and take on record the Un-Audited Financial Results of the Company under Indian Accounting Standards (Ind-As) for the quarter and half year ended September 30 2022. The Company shall intimate to the exchanges the Un-Audited financial results upon the conclusion of the aforesaid Board Meeting and will arrange for the announcement of the same in the Press and on the companys website as required under the Listing Agreement. We wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Monday, November 14, 2022, the Board has considered and took on record the Un-Audited Standalone Financial Results of the Company for the quarter and half year ended September 30, 2022, which is enclosed herewith along with the Statement of Asset & Liabilities, Cash Flow Statement and the Limited Review Report of the Statutory Auditor of the Company. We wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Monday, November 14, 2022, the Board has considered and took on record the Un-Audited Standalone Financial Results of the Company for the quarter and half year ended September 30, 2022, which is enclosed herewith along with the Statement of Asset & Liabilities, Cash Flow Statement and the Limited Review Report of the Statutory Auditor of the Company. The meeting of the Board of Directors of the Company commenced at 14:00 hrs and concluded at 15:30 hrs. (As Per BSE Announcement Dated on 14.11.2022) As per requirement of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, we enclose herewith copies of advertisement of the Extract of the Standalone Un-Audited Financial Results for the quarter ended September 30, 2022 as published in newspapers pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. The advertisement is published in the Baroda Edition of 'Indian Express', English Edition & 'Vadodara Samachar', Gujarati Edition on November 15, 2022. (As Per BSE Announcement Dated on 24/11/2022)

1 2

LOGIN HERE

Samrat Pharmachem Ltd

Board Meeting